Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 96,500 shares, a growth of 59.2% from the January 31st total of 60,600 shares. Approximately 1.5% of the company’s stock are short sold. Based on an average daily volume of 813,300 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ADIL shares. Rodman & Renshaw began coverage on Adial Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $8.00 price objective for the company. RODMAN&RENSHAW raised Adial Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th.

Institutional Investors Weigh In On Adial Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Citadel Advisors LLC raised its stake in Adial Pharmaceuticals by 63.8% in the 4th quarter. Citadel Advisors LLC now owns 54,508 shares of the company’s stock worth $55,000 after acquiring an additional 21,238 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Adial Pharmaceuticals in the fourth quarter valued at about $48,000. Finally, Geode Capital Management LLC increased its holdings in shares of Adial Pharmaceuticals by 36.0% in the fourth quarter. Geode Capital Management LLC now owns 61,847 shares of the company’s stock valued at $62,000 after purchasing an additional 16,381 shares during the period. 16.41% of the stock is owned by hedge funds and other institutional investors.

Adial Pharmaceuticals Price Performance

NASDAQ:ADIL opened at $0.79 on Monday. Adial Pharmaceuticals has a twelve month low of $0.72 and a twelve month high of $3.60. The company’s 50 day moving average is $0.91 and its two-hundred day moving average is $0.99.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.